Plain-English translation of NCT05236114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The GEMINI-NSCLC study is tracking lung cancer patients over time by collecting blood samples alongside their regular cancer care. Researchers want to understand how lung cancer evolves as patients receive standard treatment, and whether special markers found in the blood—called circulating tumor DNA—can predict who will do well and who might have their cancer come back.
Currently, doctors have limited ways to predict which lung cancer patients will stay cancer-free long-term or may need additional treatment. This study hopes to identify blood-based markers that could help doctors personalize care and catch recurrence earlier.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive your standard cancer treatment as planned—either surgery with or without chemotherapy for early-stage cancer, or immunotherapy for advanced cancer. The only additional requirement is providing extra blood samples during your routine follow-up visits so researchers can monitor how your cancer's DNA changes over time. The study will follow you long-term as part of your normal cancer surveillance.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States